Evidence map›Paper›PMID 28776170›Full record

ArticleFolia microbiologica2018

Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience.

J Radocha, P Paterová, A Zavřelová, B Víšek, F Gabalec, H Žemličková, P Žák

Abstract read
PubMed Publisher
In one paragraph

Article in Folia microbiologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Hangeshashinto for prevention of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a randomized phase II study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

J Radocha4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic. jakub.radocha@centrum.cz.ORCID http://orcid.org/0000-0002-5384-8238
P PaterováInstitute of Clinical Microbiology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
A Zavřelová4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
B Víšek4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
F Gabalec4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
H ŽemličkováInstitute of Clinical Microbiology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
P Žák4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
Charles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viridans group streptococci bloodstream infections (VGS BSI) remain a significant cause of mortality and morbidity in patients with severe neutropenia. The goal of our study was to evaluate clinical course and microbiological susceptibility of VGS BSI at our center. Retrospective analysis of all microbiologically documented bloodstream infections caused by VGS during the 9-year time period (from January 2006 until December 2014) was carried out. Only patients with severe neutropenia (< 500/μL) were included in the study. Clinical outcome and microbiological susceptibility pattern of isolates were recorded. Fifty-one individual patients with episode of VGS BSI were identified. The most frequent agent was Streptococcus mitis (23/51 cases, 45.1%). 88.2% (45/51) of patients were on recommended ciprofloxacin prophylaxis. 20/51 (39.2%) of patients suffered from mucositis at the time of diagnosis (10 patients had oral mucositis, 2 patients had bowel mucositis, and 8 patients both). Twenty-six patients (51.0%) had clinically relevant lung damage caused by VGS BSI (i.e., acute lung injury or acute respiratory distress syndrome). Twenty-four (47.0%) patients presented with bilateral lung infiltrated upon chest imaging, and two (4.0%) patients had unilateral lung infiltrates. Three patients (5.9%) died due to VGS BSI until day 28 of observation. No difference in signs of shock syndrome was observed in the patients during transplantation procedures compared to patients without transplantation as well as in a group received previous high-dose chemotherapy with cytosinarabinoside or in patients with mucositis. Only 3/51 of isolates (5.9%) were resistant to penicillin. All isolates were susceptible to empirical treatment. While the penicillin resistance of VGS remains low in middle Europe, initial antibiotic therapy of febrile neutropenia are still effective in most cases. The mortality and complication rates of VGS BSI were comparable to other studies, and no specific risk factor of shock presence could be identified.

Indexed as

AdultAgedAnti-Bacterial AgentsBacteremiaFemaleHematologic NeoplasmsHumansMaleMiddle AgedRetrospective StudiesStreptococcal InfectionsViridans StreptococciYoung AdultAnti-Bacterial Agents

Identifiers

PMID28776170
OpenAlexW2742829672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.